FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / J Gen Virol / An inactivated Vero cell-grown Japanese encephalitis vaccine...
The Journal of general virology2010; 91(Pt 6); 1407-1417; doi: 10.1099/vir.0.019190-0

An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses.

Abstract: Advax is a polysaccharide-based adjuvant that potently stimulates vaccine immunogenicity without the increased reactogenicity seen with other adjuvants. This study investigated the immunogenicity of a novel Advax-adjuvanted Vero cell culture candidate vaccine against Japanese encephalitis virus (JEV) in mice and horses. The results showed that, in mice, a two-immunization, low-dose (50 ng JEV antigen) regimen with adjuvanted vaccine produced solid neutralizing immunity comparable to that elicited with live ChimeriVax-JE immunization and superior to that elicited with tenfold higher doses of a traditional non-adjuvanted JEV vaccine (JE-VAX; Biken Institute) or a newly approved alum-adjuvanted vaccine (Jespect; Novartis). Mice vaccinated with the Advax-adjuvanted, but not the unadjuvanted vaccine, were protected against live JEV challenge. Equine immunizations against JEV with Advax-formulated vaccine similarly showed enhanced vaccine immunogenicity, confirming that the adjuvant effects of Advax are not restricted to rodent models. Advax-adjuvanted JEV vaccine elicited a balanced T-helper 1 (Th1)/Th2 immune response against JEV with protective levels of cross-neutralizing antibody against other viruses belonging to the JEV serocomplex, including Murray Valley encephalitis virus (MVEV). The adjuvanted JEV vaccine was well tolerated with minimal reactogenicity and no systemic toxicity in immunized animals. The cessation of manufacture of traditional mouse brain-derived unadjuvanted JEV vaccine in Japan has resulted in a JEV vaccine shortage internationally. There is also an ongoing lack of human vaccines against other JEV serocomplex flaviviruses, such as MVEV, making this adjuvanted, cell culture-grown JEV vaccine a promising candidate to address both needs with one vaccine.
Get Full Text
Publication Date: 2010-02-03 PubMed ID: 20130134PubMed Central: PMC2888167DOI: 10.1099/vir.0.019190-0Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • N.I.H.
  • Extramural

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The study discusses the enhanced potential of a new vaccine called Advax-adjuvanted Vero cell culture candidate against Japanese encephalitis virus (JEV) in mice and horses. It shows that this vaccine can induce a strong immune response at much lower doses than traditional JEV vaccines and provides broad protection against JEV and related viruses.

Aims and Methods of the Study

  • The primary aim of this study was to investigate the immunogenicity, or the ability of a vaccine to stimulate an immune response, of a new Japanese encephalitis virus (JEV) vaccine called Advax-adjuvanted Vero cell culture candidate.
  • The researchers carried out the study on mice and horses, using different doses of the Advax-adjuvanted vaccine and comparing it with other JEV vaccines such as ChimeriVax-JE, JE-VAX, and Jespect.
  • They also examined the survival rates of mice post live JEV exposure and the immunogenicity of the Advax-adjuvanted vaccine in horses to confirm its effectiveness in different animal models.
  • The study further explored the vaccine’s ability to elicit a balanced T-helper 1 (Th1)/Th2 immune response against JEV and related viruses.

Key Findings of the Study

  • The study found that the Advax-adjuvanted vaccine could induce a robust neutralizing immunity in mice, similar to live ChimeriVax-JE immunization and superior to traditional non-adjuvanted JEV vaccines (JE-VAX) or alum-adjuvanted vaccines (Jespect).
  • Only mice vaccinated with the Advax-adjuvanted vaccine survived live JEV challenge, demonstrating its potential protective capability.
  • The effectiveness of the Advax-adjuvanted JEV vaccine was also confirmed in horses, establishing the broader relevance of the vaccine across species.
  • The vaccine elicited a balanced Th1/Th2 immune response and provided protective levels of cross-neutralizing antibody against other viruses belonging to the JEV serocomplex such as the Murray Valley encephalitis virus (MVEV).
  • The Advax-adjuvanted JEV vaccine was well tolerated with minimal side effects and no systemic toxicity observed in immunized animals.

Significance and Implications

  • The findings of this study are significant as they reveal the promising potential of the Advax-adjuvanted vaccine in addressing the global shortage of traditional mouse-brain derived unadjuvanted JEV vaccines and the lack of human vaccines for other JEV serocomplex flaviviruses like MVEV.
  • The study establishes that Advax, as an adjuvant, is capable of enhancing the efficacy of a JEV vaccine at much lower doses, without increasing adverse reactions.
  • Thus, the Advax-adjuvanted Vero cell culture candidate vaccine for JEV could be a key solution to address the unmet need for effective and well-tolerated vaccines against Japanese encephalitis and related diseases.

Cite This Article

APA
Lobigs M, Pavy M, Hall RA, Lobigs P, Cooper P, Komiya T, Toriniwa H, Petrovsky N. (2010). An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses. J Gen Virol, 91(Pt 6), 1407-1417. https://doi.org/10.1099/vir.0.019190-0

Publication

The Journal of general virology
ISSN: 1465-2099
NlmUniqueID: 0077340
Country: England
Language: English
Volume: 91
Issue: Pt 6
Pages: 1407-1417

Researcher Affiliations

Lobigs, Mario
  • John Curtin School of Medical Research, The Australian National University, Canberra, ACT 2601, Australia. Mario.Lobigs@anu.edu.au
Pavy, Megan
    Hall, Roy A
      Lobigs, Päivi
        Cooper, Peter
          Komiya, Tomoyoshi
            Toriniwa, Hiroko
              Petrovsky, Nikolai

                MeSH Terms

                • Adjuvants, Immunologic / administration & dosage
                • Animals
                • Antibodies, Neutralizing / blood
                • Antibodies, Viral / blood
                • Chlorocebus aethiops
                • Cross Reactions
                • Encephalitis, Japanese / prevention & control
                • Female
                • Flavivirus / immunology
                • Horses
                • Inulin / administration & dosage
                • Inulin / analogs & derivatives
                • Japanese Encephalitis Vaccines / administration & dosage
                • Japanese Encephalitis Vaccines / immunology
                • Mice
                • Mice, Inbred BALB C
                • Mice, Inbred C57BL
                • Survival Analysis
                • Th1 Cells / immunology
                • Th2 Cells / immunology
                • Vaccination / methods
                • Vaccines, Inactivated / administration & dosage
                • Vaccines, Inactivated / immunology
                • Vero Cells

                Grant Funding

                • HHSN272200800039C / NIAID NIH HHS
                • U01 AI061142 / NIAID NIH HHS
                • U01-AI061142 / NIAID NIH HHS

                References

                This article includes 54 references
                1. Appaiahgari MB, Vrati S. Immunogenicity and protective efficacy in mice of a formaldehyde-inactivated Indian strain of Japanese encephalitis virus grown in Vero cells. Vaccine 22, 3669–3675.
                  pubmed: 15315846
                2. Barrett AD, Gould EA. Comparison of neurovirulence of different strains of yellow fever virus in mice. J Gen Virol 67, 631–637.
                  pubmed: 3958694
                3. Beasley DW, Lewthwaite P, Solomon T. Current use and development of vaccines for Japanese encephalitis. Expert Opin Biol Ther 8, 95–106.
                  pubmed: 18081539
                4. Broom AK, Wallace MJ, Mackenzie JS, Smith DW, Hall RA. Immunization with gamma globulin of Murray Valley encephalitis virus and with an inactivated Japanese encephalitis virus vaccine as prophylaxis against Australian encephalitis: evaluation in a mouse model. J Med Virol 61, 259–265.
                  pubmed: 10797383
                5. Chu JH, Chiang CC, Ng ML. Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection. J Immunol 178, 2699–2705.
                  pubmed: 17312111
                6. Colombage G, Hall R, Pavy M, Lobigs M. DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. Virology 250, 151–163.
                  pubmed: 9770429
                7. Coutelier JP, van der Logt JT, Heessen FW, Warnier G, Van Snick J. IgG2a restriction of murine antibodies elicited by viral infections. J Exp Med 165, 64–69.
                  pmc: PMC2188250pubmed: 3794607
                8. Ferguson M, Kurane I, Wimalaratne O, Shin J, Wood D. WHO informal consultation on the scientific basis of specifications for production and control of inactivated Japanese encephalitis vaccines for human use, Geneva, Switzerland, 1–2 June 2006. Vaccine 25, 5233–5243.
                  pubmed: 17590244
                9. Ferguson M, Johnes S, Li L, Heath A, Barrett A. Effect of genomic variation in the challenge virus on the neutralization titres of recipients of inactivated JE vaccines – report of a collaborative study on PRNT50 assays for Japanese encephalitis virus (JE) antibodies. Biologicals 36, 111–116.
                  pubmed: 17892945
                10. Fischer M, Casey C, Chen RT. Promise of new Japanese encephalitis vaccines. Lancet 370, 1806–1808.
                  pubmed: 18061040
                11. Goverdhan MK, Kulkarni AB, Gupta AK, Tupe CD, Rodrigues JJ. Two-way cross-protection between West Nile and Japanese encephalitis viruses in bonnet macaques. Acta Virol 36, 277–283.
                  pubmed: 1360756
                12. Gupta RK. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 32, 155–172.
                  pubmed: 10837642
                13. Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60, 421–467.
                  pubmed: 14689700
                14. Halstead SB, Tsai TF. Japanese encephalitis vaccines. Vaccines 4th edn, pp. 919–958.
                15. Hammon WM, Sather GE. Immunity of hamsters to West Nile and Murray Valley viruses following immunization with St Louis and Japanese B. Proc Soc Exp Biol Med 91, 521–524.
                  pubmed: 13322987
                16. Hawkes RA. Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls. Aust J Exp Biol Med Sci 42, 465–482.
                  pubmed: 14202187
                17. Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laorakapongse T, Innis BL, Kotchasenee S, Gingrich JB, Latendresse J. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 319, 608–614.
                  pubmed: 2842677
                18. Hombach J, Solomon T, Kurane I, Jacobson J, Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2–3 September, 2004. Vaccine 23, 5205–5211.
                  pubmed: 16055233
                19. Huber VC, McKeon RM, Brackin MN, Miller LA, Keating R, Brown SA, Makarova N, Perez DR, Macdonald GH. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 13, 981–990.
                  pmc: PMC1563571pubmed: 16960108
                20. Huisman W, Martina BE, Rimmelzwaan GF, Gruters RA, Osterhaus AD. Vaccine-induced enhancement of viral infections. Vaccine 27, 505–512.
                  pmc: PMC7131326pubmed: 19022319
                21. Kanesa-Thasan N, Putnak JR, Mangiafico JA, Saluzzo JE, Ludwig GV. Short report: absence of protective neutralizing antibodies to West Nile virus in subjects following vaccination with Japanese encephalitis or dengue vaccines. Am J Trop Med Hyg 66, 115–116.
                  pubmed: 12135278
                22. Konishi E, Suzuki T. Ratios of subclinical to clinical Japanese encephalitis (JE) virus infections in vaccinated populations: evaluation of an inactivated JE vaccine by comparing the ratios with those in unvaccinated populations. Vaccine 21, 98–107.
                  pubmed: 12443667
                23. Kuzuhara S, Nakamura H, Hayashida K, Obata J, Abe M, Sonoda K, Nishiyama K, Sugawara K, Takeda K. Non-clinical and phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine. Vaccine 21, 4519–4526.
                  pubmed: 14575762
                24. Licon Luna RM, Lee E, Müllbacher A, Blanden RV, Langman R, Lobigs M. Lack of both Fas ligand and perforin protects from flavivirus-mediated encephalitis in mice. J Virol 76, 3202–3211.
                  pmc: PMC136025pubmed: 11884544
                25. Lobigs M, Pavy M, Hall RA. Cross-protective and infection-enhancing immunity in mice vaccinated against flaviviruses belonging to the Japanese encephalitis virus serocomplex. Vaccine 21, 1572–1579.
                  pubmed: 12639478
                26. Lobigs M, Larena M, Alsharifi M, Lee E, Pavy M. Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus. J Virol 83, 2436–2445.
                  pmc: PMC2648276pubmed: 19109382
                27. Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 10, S98–S109.
                  pubmed: 15577938
                28. Markine-Goriaynoff D, Coutelier JP. Increased efficacy of the immunoglobulin G2a subclass in antibody-mediated protection against lactate dehydrogenase-elevating virus-induced polioencephalomyelitis revealed with switch mutants. J Virol 76, 432–435.
                  pmc: PMC135718pubmed: 11739710
                29. Martin RM, Brady JL, Lew AM. The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J Immunol Methods 212, 187–192.
                  pubmed: 9672206
                30. Martina BE, Koraka P, van den Doel P, van Amerongen G, Rimmelzwaan GF, Osterhaus AD. Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus. Vaccine 26, 153–157.
                  pmc: PMC7127062pubmed: 18069096
                31. McKee AS, Munks MW, Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity 27, 687–690.
                  pubmed: 18031690
                32. Moghaddam A, Olszewska W, Wang B, Tregoning JS, Helson R, Sattentau QJ, Openshaw PJ. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 12, 905–907.
                  pubmed: 16862151
                33. Monath TP. Japanese encephalitis vaccines: current vaccines and future prospects. Curr Top Microbiol Immunol 267, 105–138.
                  pubmed: 12082985
                34. Monath TP. Editorial: Jennerian vaccination against West Nile virus. Am J Trop Med Hyg 66, 113–114.
                  pubmed: 12135277
                35. Monath TP, Guirakhoo F, Nichols R, Yoksan S, Schrader R, Murphy C, Blum P, Woodward S, McCarthy K. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 188, 1213–1230.
                  pubmed: 14551893
                36. Mullbacher A, Lobigs M, Lee E. Immunobiology of mosquito-borne encephalitic flaviviruses. Adv Virus Res 60, 87–120.
                  pubmed: 14689692
                37. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310, 1510–1512.
                  pubmed: 16322460
                38. Petrovsky N. Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. Vaccine 24 (Suppl. 2), 26–29.
                  pmc: PMC3101117pubmed: 16823913
                39. Petrovsky N. Freeing vaccine adjuvants from dangerous immunological dogma. Expert Rev Vaccines 7, 7–10.
                  pubmed: 18251687
                40. Polack FP. Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple. Pediatr Res 62, 111–115.
                  pubmed: 17515829
                41. Poland JD, Cropp CB, Craven RB, Monath TP. Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants. J Infect Dis 161, 878–882.
                  pubmed: 2324539
                42. Ranasinghe C, Ramshaw IA. Genetic heterologous prime–boost vaccination strategies for improved systemic and mucosal immunity. Expert Rev Vaccines 8, 1171–1181.
                  pubmed: 19722891
                43. Silva DG, Cooper PD, Petrovsky N. Inulin-derived adjuvants efficiently promote both Th1 and Th2 immune responses. Immunol Cell Biol 82, 611–616.
                  pubmed: 15550119
                44. Solomon T. Flavivirus encephalitis. N Engl J Med 351, 370–378.
                  pubmed: 15269317
                45. Srivastava AK, Putnak JR, Lee SH, Hong SP, Moon SB, Barvir DA, Zhao B, Olson RA, Kim SO. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine 19, 4557–4565.
                  pubmed: 11483284
                46. Sugawara K, Nishiyama K, Ishikawa Y, Abe M, Sonoda K, Komatsu K, Horikawa Y, Takeda K, Honda T. Development of Vero cell-derived inactivated Japanese encephalitis vaccine. Biologicals 30, 303–314.
                  pubmed: 12421588
                47. Takasaki T, Yabe S, Nerome R, Ito M, Yamada K, Kurane I. Partial protective effect of inactivated Japanese encephalitis vaccine on lethal West Nile virus infection in mice. Vaccine 21, 4514–4518.
                  pubmed: 14575761
                48. Tang F, Zhang JS, Liu W, Zhao QM, Zhang F, Wu XM, Yang H, Ly H, Cao WC. Failure of Japanese encephalitis vaccine and infection in inducing neutralizing antibodies against West Nile virus, People's Republic of China. Am J Trop Med Hyg 78, 999–1001.
                  pubmed: 18541783
                49. Tauber E, Kollaritsch H, Korinek M, Rendi-Wagner P, Jilma B, Firbas C, Schranz S, Jong E, Klingler A. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 370, 1847–1853.
                  pubmed: 18061060
                50. Toriniwa H, Komiya T. Long-term stability of Vero cell-derived inactivated Japanese encephalitis vaccine prepared using serum-free medium. Vaccine 26, 3680–3689.
                  pubmed: 18534722
                51. Tsai TF, Popovici F, Cernescu C, Campbell GL, Nedelcu NI. West Nile encephalitis epidemic in southeastern Romania. Lancet 352, 767–771.
                  pubmed: 9737281
                52. Wallace MJ, Smith DW, Broom AK, Mackenzie JS, Hall RA, Shellam GR, McMinn PC. Antibody-dependent enhancement of Murray Valley encephalitis virus virulence in mice. J Gen Virol 84, 1723–1728.
                  pubmed: 12810865
                53. Williams DT, Daniels PW, Lunt RA, Wang LF, Newberry KM, Mackenzie JS. Experimental infections of pigs with Japanese encephalitis virus and closely related Australian flaviviruses. Am J Trop Med Hyg 65, 379–387.
                  pubmed: 11693888
                54. Yang KD, Yeh WT, Yang MY, Chen RF, Shaio MF. Antibody-dependent enhancement of heterotypic dengue infections involved in suppression of IFNγ production. J Med Virol 63, 150–157.
                  pubmed: 11170052
                Subscribe to our newsletter
                Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.